| Metabolic Dysfunction-Associated Steatohepatitis |
2019-001987-31: Combined Treatment of fatty liver Inflammation and type 2 diabetes Kombinierte Behandlung der Fettleberentzündung und Typ 2 Diabetes |
|
|
| Not yet recruiting | 4 | 142 | Europe | Film-coated tablet, Solution for injection in pre-filled pen, Jardiance, Ozempic | Deutsche Diabetes Forschungsgesellschaft e.V., German Center for Diabetes Research (DZD e.V), Boehringer Ingelheim Pharma GmbH, Novo Nordisk A/S | Diabetes mellitus type 2 (T2D) and non-alcoholic steatohepatitis (NASH) Typ 2 Diabetes und nicht-alkoholische Fettleberentzündung, Type 2 Diabetes and non-alcoholic fatty liver inflammation Typ 2 Diabetes und nicht-alkoholbedingte Fettleberentzündung, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
NCT04976283: Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver |
|
|
| Recruiting | 4 | 123 | RoW | Pioglitazone, Zolid, Empagliflozin, Diampa, Pioglitazone + Empagliflozin, Zolid + Diampa | Getz Pharma | Diabetes Mellitus, Type 2, NASH - Nonalcoholic Steatohepatitis, NAFLD | 05/23 | 11/23 | | |
| Not yet recruiting | 4 | 93 | Europe | dulaglutide (TRULICITY®) 1.5 mg, reinforced dietary monitoring | Central Hospital, Nancy, France, Eli Lilly and Company | Diabetes Mellitus, Type 2, NASH - Nonalcoholic Steatohepatitis | 09/23 | 03/24 | | |
| Recruiting | 4 | 192 | Europe | Empagliflozin 10mg oral tablet / Semaglutide 1mg pen injector, Jardiance(R), Ozempic(R), Empagliflozin 10mg oral tablet and placebo pen injector matching semaglutide, Jardiance(R), Placebo matching empagliflozin and placebo pen injector matching semaglutide, Control / Placebo | The Deutsche Diabetes Forschungsgesellschaft e.V., Boehringer Ingelheim, German Center for Diabetes Research, Federal Ministry of Health, Germany, Ministry of Innovation, Science and Research in North Rhine-Westphalia, Novo Nordisk A/S | Type 2 Diabetes, Non-alcoholic Steatohepatitis (NASH), Non-alcoholic Fatty Liver Disease (NAFLD) | 01/25 | 12/25 | | |
Ertu-NASH, NCT05644717: Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLD |
|
|
| Not yet recruiting | 4 | 164 | NA | Ertugliflozin 5 mg, 15mg | Getz Pharma | Liver Fat, Liver Fibrosis, Glycemic Control, Body Weight Changes, Waist Circumference, Tolerance | 03/24 | 03/24 | | |
| Enrolling by invitation | 4 | 140 | Canada | Semaglutide Treatment, Sitagliptin 100mg | University Health Network, Toronto, Novo Nordisk A/S | Liver Transplant; Complications, Diabetes Mellitus, NASH - Nonalcoholic Steatohepatitis, NAFLD | 04/24 | 12/24 | | |
2019-002073-56: A study to investigate the efficacy and safety of Aramchol in patients with a form of fatty liver disease. |
|
|
| Not yet recruiting | 3/4 | 2000 | Europe | Aramchol, Tablet | Galmed Research and Development, Ltd., Galmed Research and Development, Ltd. | Nonalcoholic Steatohepatitis (NASH), NASH is a chronic liver disease caused by the build-up of too much fat in the liver, along with inflammation and liver damage., Diseases [C] - Digestive System Diseases [C06] | | | | |
